SCHEMBL14448704

SCHEMBL14448704

COC(=O)C(NC(=O)c1n[nH]c(NC(=O)c2ccccc2Cl)c1Br)c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 8/20 0.70
TACR3 P29371 8/20 0.46
LMNA P02545 1/20 0.43
KMT2A Q03164 2/20 0.43
F2 P00734 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TACR2 P21452 3/20 0.40
TSHR P16473 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
NFKB1 P19838 1/20 0.40
MTOR P42345 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6510482 1.00 BDKRB1 (0.70) BDKRB1TACR3LMNAKMT2AF2
SCHEMBL5794807 1.00 BDKRB1 (0.70) BDKRB1TACR3LMNAKMT2AF2
SCHEMBL14448722 0.93 BDKRB1 (0.61) BDKRB1TACR3LMNAKMT2AF2
SCHEMBL14448705 0.90 BDKRB1 (0.57) BDKRB1KMT2AF2MAPTHPGD
SCHEMBL5823069 0.90 BDKRB1 (0.57) BDKRB1KMT2AF2MAPTHPGD
SCHEMBL6512274 0.88 BDKRB1 (0.55) BDKRB1TACR3KMT2AF2MAPT
SCHEMBL6513485 0.88 BDKRB1 (0.69) BDKRB1TACR3KMT2AF2MAPT
SCHEMBL4703867 0.87 BDKRB1 (0.54) BDKRB1LMNAKMT2AF2MAPT
SCHEMBL14084803 0.86 BDKRB1 (0.68) BDKRB1LMNAKMT2AHPGDSMN1; SMN2
SCHEMBL14084789 0.86 BDKRB1 (0.68) BDKRB1LMNAKMT2AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161633-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2007-07-12 US disclosed
US-20070161633-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161633-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases BDKRB1, BDKRB2, HRH2 BDKRB1 1/4885TACR3 496/4885LMNA 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.